Universal Influenza Vaccines 2020

28-30 September 2020, Richard Doll Building, University of Oxford, Oxford, UK

  • Increase font size
  • Default font size
  • Decrease font size

Day One

Provisional Conference Programme | Monday 28th September 2020

Welcome to Oxford & Opening Remarks
Sarah Gilbert
(The Jenner Institute, University of Oxford, Oxford, UK)

SESSION 1:
OPENING PLENARY SESSION

Moderator: Sarah Gilbert
(The Jenner Institute, University of Oxford, Oxford, UK)

‘A global perspective on universal influenza vaccines: What do we want and how will we use it?’
Christopher Chadwick, Martin Friede and Ann Moen
(World Health Organization, Geneva, Switzerland)

‘Scientific steps from the Spanish Influenza era have provided a firm foundation for both conventional and exploratory new influenza vaccines’
John S. Oxford and D. Gill
(Blizard Institute, Queen Mary College, London, UK)

‘Achieving better influenza vaccines: Implementation of NIAID's strategic plan for universal influenza vaccine development’
Jennifer Gordon
(Respiratory Diseases Branch, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, HHS, Behesda, Maryland, USA)

‘What is a Universal Influenza Vaccine? Is it possible?’
Rob Lambkin-Williams
(Virology Consult, London, UK)

Coffee Break & Poster Set-Up

SESSION 2:
UNIVERSAL VACCINES

Moderator: John Oxford
(Blizard Institute, Queen Mary College, London, UK)

‘The development of a new approach to influenza vaccination, from concept to efficacy testing’
Sarah Gilbert
(The Jenner Institute, University of Oxford, Oxford, UK)

‘Development of a universal influenza vaccine technology landscape’
Julie Ostrowsky
(Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota, Minneapolis, Minnesota, USA)

‘Development of universal influenza vaccines in Russia’
Yuri Vasiliev
(St. Petersburg Research Institute of Vaccines and Sera, St. Petersburg, Russian Federation)

Lunch Break & Posters

SESSION 3:
SUBTYPES/EPITOPES

Moderator: Anke L.W. Huckriede
(University Medical Center Groningen, Groningen, The Netherlands)

‘From subtype coverage to universal flu vaccines’
Shan Lu
(University of Massachusetts, Worcester, Massachusetts, USA)

‘Utilising epitopes of limited variability to produce a broadly neutralising influenza vaccine’
Craig P. Thompson1,2, Uri Obsolski1,2, Alex Fyfe1,2, Jose Lourenco1,2, Daniel O’Connor3, Teresa Lambe4, Christine Rollier3, Andrew Pollard3 and Sunetra Gupta1,2
(1 Department of Zoology, University of Oxford, Oxford, UK; 2 Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK; 3 Oxford Vaccine Group, Department of Paediatrics and the NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK; 4 Jenner Institute, University of Oxford, Oxford, UK)

‘Targeting highly conserved influenza A and B virus epitopes with nanoparticle-based vaccines’
David F. Zeigler, Emily Gage and Christopher H. Clegg
(TRIA Bioscience Corp, Seattle Washington, USA)

‘Permissive and preferential cell-lines for challenge agent and vaccine manufacture’
Adrian Wildfire
(SGS, Camberley, UK)

Tea Break & Posters

SESSION 4:
STANDARDISATION/ASSAYS/CORRELATES OF PROTECTION

Moderator: To be confirmed

‘Standardisation of serology assays used in the evaluation of vaccines’
Othmar G. Engelhardt
(NIBSC, South Mimms, Potters Bar, UK)

‘Correlates of protection for influenza vaccines’
Emanuele Montomoli
(VisMederi SRl, Siena, Italy)

 

UIV 2020 Delegates

Login details will be supplied after you have registered for the event.


UIV 2020 Sponsors

  • FluConsult
  • Sanofi Pasteur
  • NanoFCM
  • Vaxart
  • BiondVax
  • Izon Science
  • The Native Antigen Company
  • APACI
  • DNAvaccine.com
  • VisMederi
  • ISIRV

UIV 2020 Downloads

UIV 2020 Leaflet

UIV 2020 Mailing List

Name
E-mail Address
What is 3+2-1?